A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
Clinical trial NCT05282771 · COMPLETED
Trial details
- NCT number
- NCT05282771
- Sponsor
- Sun Pharmaceutical Industries, Inc.
- Status
- COMPLETED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-16
- Primary completion
- 2022-02-10
- Enrollment
- 402
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.